Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of isavuconazonium sulfate in Japanese pediatric patients at high risk of deep mycosis
jRCT2021260026Phase 2Recruiting
- Sponsor
- Asahi Kasei Corporation
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isavuconazonium in Deep Mycoses, sponsored by Asahi Kasei Corporation. Primary endpoints: Treatment-emergent adverse events, Vital signs and 2 more. Started Sep 2026; status: recruiting.
02
Drugs
isavuconazonium
03
Conditions
Deep Mycoses
Beyond the preview
Go deeper on jRCT2021260026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021260026.